Date: 2015-12-03
Type of information: Nomination
Compound:
Company: Acacia Pharma (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 3, 2015, Acacia Pharma, a supportive care company, announced that Ian Kent will retire as non-executive Chairman on 31st December 2015 and will be succeeded by Dr Patrick Vink. Patrick Vink most recently served as chief operating officer of Cubist Pharmaceuticals, joining there from senior roles at Mylan, including having global responsibility for the group’s hospital business. Previously Patrick held several leadership positions with Novartis Sandoz, Sanofi and Biogen, principally in global commercial roles. He is also a non-executive director of Inhibikase. and Micreos.
Financial terms:
Latest news:
